Stereotaxis, Inc.
STXS
Positions held
Your positionsSTXS isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $111.22M | Enterprise value | $111.14M | Trailing P/E | — | Forward P/E | -7.16 |
| PEG | 1.31 | Price / book | 8.88 | Beta | 1.37 | Dividend yield | 0.00% |
| Revenue growth | -12.8% | Earnings growth | — | Gross margin | 55.6% | Operating margin | -59.6% |
| Profit margin | -74.2% | ROE | -1.8% | ROA | -25.4% | Debt / equity | 0.30 |
| Current ratio | 1.42 | Free cash flow | -$8.83M | Analyst recommendation | none | Mean target | $3.00 |
| 52w high | $3.42 | 52w low | $1.09 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $7.7M | $6.3M | $8.6M | $7.5M | $8.8M |
| Op margin | -59.6% | -95.1% | -65.4% | -87.8% | -45.2% |
| Net income | -$4.5M | -$5.9M | -$5.5M | -$6.5M | -$3.8M |
| Gross margin | 58.5% | 60.3% | 50.1% | 54.9% | 52.0% |
| Gross profit | $4.5M | $3.8M | $4.3M | $4.1M | $4.6M |
| Operating income | -$4.6M | -$6.0M | -$5.6M | -$6.6M | -$4.0M |
- Revenue +22% vs prior quarter ($7.7M vs $6.3M).
- Gross margin 58.5% (was 60.3% prior quarter).
- Operating margin expanded to -59.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $32.4M | $26.9M | $26.8M | $28.1M | — |
| Op margin | -68.3% | -91.9% | -81.6% | -66.7% | — |
| Net income | -$21.6M | -$24.0M | -$20.7M | -$18.3M | — |
| Gross margin | 52.7% | 54.2% | 55.5% | 65.6% | — |
| Gross profit | $17.1M | $14.6M | $14.9M | $18.5M | — |
| Operating income | -$22.1M | -$24.7M | -$21.8M | -$18.8M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-16 · Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society’s HRX 2026
2026-09-14 · Can AI Keep ISRG Ahead of Rising Robotic Surgery Competition?
2026-09-03 · University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program
2026-08-18 · Stereotaxis (STXS) Q2 2026 Earnings Call Transcript
2026-08-12 · ISRG's US Procedure Growth Slows: Is ACA Headwind a Temporary Concern?
2026-08-12 · Stereotaxis, Inc. Q2 2026 Earnings Call Summary
2026-08-12 · Stereotaxis Q2 Earnings Call Highlights
2026-08-11 · Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates
2026-08-11 · Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates
2026-08-06 · Teleflex (TFX) Surpasses Q2 Earnings and Revenue Estimates
2026-08-03 · Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates
2026-08-03 · Mobia Medical Appoints Myriam Curet, M.D., to its Board of Directors
Price (daily)
Full chart · RSI · MACD · patterns